Quantitative measurement and imaging of drug-uptake by bacteria with antimicrobial resistance

Short Name: MetVBadBugs, Project Number: 15HLT01
Large escherichia coli bacteria

Innovative imaging techniques will support the development of improved antibiotics to beat resistant bacteria

In Europe, antimicrobial resistance is responsible for approximately 25 000 deaths a year with annual treatment and social costs estimated at around €1.5 billion. Drug-resistant Gram-negative bacteria are responsible for two thirds of these deaths and a key measurement challenge surrounds the effective penetration of antibiotic drugs into the bacteria. These bacteria have a double membrane and protein pumps that rapidly remove antimicrobial drugs that penetrate the membrane, before they can take effect. Although many of the molecular mechanisms involved in these steps are known, the dynamics of each step are unclear. This project developed innovative measurement capabilities that will be able to quantify and image the penetration of drugs into Gram-negative bacteria and measure the accumulation and removal of the drug. The tools and understanding generated will provide vital help to scientists optimising antimicrobial drugs to combat these deadly bacteria. 


Coordinator: Paulina Rakowska


For more information, please contact the EURAMET Management Support Unit:

Phone: +44 20 8943 6666

E-mail: empir.msu@euramet.org

Project website
Other Participants
GlaxoSmithKline Research and Development Ltd. (United Kingdom)
ION-TOF Technologies GmbH (Germany)
Laboratorio Europeo di Spettroscopie Non Lineari (Italy)
Smith & Nephew Medical Limited (United Kingdom)
Specs Surface Nano Analysis GmbH (Germany)
The Francis Crick Institute Limited (United Kingdom)
The University of Nottingham (United Kingdom)